FDA OKs Jazz Pharma’s lurbinectedin for lung cancer

Under accelerated review status, the FDA approves Jazz Pharmaceuticals’ (JAZZ +4.6%) Zepzelca (lurbinectedin) for adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemo.

The company in-licensed U.S. rights from Spanish drugmaker PharmaMar (OTCPK:PHMMF +2.8%) in December 2019.

Lurbinectedin is an alkylating agent that kills cancer cells by interrupting the DNA replication process.

https://seekingalpha.com/news/3583139-fda-oks-jazz-pharmas-lurbinectedin-for-lung-cancer